Vertex Pharmaceuticals 관리
관리 기준 확인 2/4
Vertex Pharmaceuticals CEO는 Reshma Kewalramani, Apr2020 에 임명되었습니다 의 임기는 4.58 년입니다. 총 연간 보상은 $ 20.59M, 7.3% 로 구성됩니다. 7.3% 급여 및 92.7% 보너스(회사 주식 및 옵션 포함). 는 $ 33.94M 가치에 해당하는 회사 주식의 0.029% 직접 소유합니다. 33.94M. 경영진과 이사회의 평균 재임 기간은 각각 5.1 년과 4.8 년입니다.
주요 정보
Reshma Kewalramani
최고 경영자
US$20.6m
총 보상
| CEO 급여 비율 | 7.3% |
| CEO 임기 | 4.6yrs |
| CEO 소유권 | 0.03% |
| 경영진 평균 재임 기간 | 5.1yrs |
| 이사회 평균 재임 기간 | 4.8yrs |
최근 관리 업데이트
Recent updates
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Nov 05Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Oct 18Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)
Oct 10Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
Sep 15Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Sep 05Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
Aug 02Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?
Jul 11
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Jul 09If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jun 20Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales
Jun 17Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Jun 04Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet
May 09Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$480m |
| Jun 30 2024 | n/a | n/a | -US$490m |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$21m | US$2m | US$4b |
| Sep 30 2023 | n/a | n/a | US$3b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$3b |
| Dec 31 2022 | US$16m | US$1m | US$3b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$3b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$15m | US$1m | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$3b |
| Dec 31 2020 | US$9m | US$1m | US$3b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$7m | US$702k | US$1b |
보상 대 시장: Reshma 의 총 보상 ($USD 20.59M )은 US 시장( $USD 12.73M ).
보상과 수익: 회사가 수익성이 없는 동안 Reshma 의 보상이 증가했습니다.
CEO
Reshma Kewalramani (51 yo)
4.6yrs
테뉴어
US$20,594,441
보상
Dr. Reshma Kewalramani, M.D., FASN, is Director at Year Up Inc. since September 2023. She had been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman | 15.3yrs | US$6.60m | 0.0040% $ 4.7m | |
| CEO, President & Director | 4.6yrs | US$20.59m | 0.029% $ 33.9m | |
| Executive VP & CFO | 5.6yrs | US$7.37m | 0.017% $ 19.8m | |
| Executive VP & COO | 3.3yrs | US$9.00m | 0.019% $ 22.3m | |
| Executive VP & Chief Scientific Officer | 9.8yrs | US$6.54m | 0.010% $ 11.6m | |
| Senior VP & Chief Accounting Officer | 3.5yrs | 데이터 없음 | 0.0029% $ 3.4m | |
| SVP and Chief Information & Data Officer | 5.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Investor Relations | 2.2yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief Legal Officer | 2.2yrs | 데이터 없음 | 0.0065% $ 7.5m | |
| Senior VP & Chief Communications Officer | 5.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Human Resources Officer | 7.3yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief Patient and External Affairs Officer | 17.3yrs | US$6.20m | 0.023% $ 26.1m |
5.1yrs
평균 재임 기간
57yo
평균 연령
경험이 풍부한 관리: VRTX 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman | 15.3yrs | US$6.60m | 0.0040% $ 4.7m | |
| CEO, President & Director | 4.8yrs | US$20.59m | 0.029% $ 33.9m | |
| Lead Independent Director | 26.8yrs | US$600.04k | 0.016% $ 17.9m | |
| Independent Director | 7.4yrs | US$537.63k | 0.0023% $ 2.6m | |
| Independent Director | 5.8yrs | US$559.79k | 0.0021% $ 2.4m | |
| Independent Director | 9.4yrs | US$550.31k | 0.0013% $ 1.5m | |
| Independent Director | 1.1yrs | US$449.08k | 데이터 없음 | |
| Independent Director | 4.4yrs | US$553.11k | 0.00064% $ 738.4k | |
| Independent Director | 2.5yrs | US$544.66k | 0.00060% $ 692.3k | |
| Independent Director | less than a year | US$407.65k | 데이터 없음 | |
| Independent Director | less than a year | 데이터 없음 | 데이터 없음 |
4.8yrs
평균 재임 기간
59yo
평균 연령
경험이 풍부한 이사회: VRTX 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.